Frederick L. Locke, MD, on Innovative CAR-T Cell Therapies: The Patient Experience
NCCN Annual Conference 2019Frederick L. Locke, MD, of the H. Lee Moffitt Cancer Center and Research Institute, discusses recent approvals of chimeric antigen receptor T-cell therapies in leukemia and lymphoma, and how clinicians are using infrastructure, navigation, and early referrals to maximize response and minimize toxicity.
Related Videos
Eric Jonasch, MD, on Kidney Cancer: A Year in Review
Eric Jonasch, MD, of The University of Texas MD Anderson Cancer Center, discusses major findings over the past 12 months in kidney cancer, including combination immunotherapies and...
Chrysalyne Schmults, MD, on Basal and Squamous Cell Carcinomas: Trends in Data and Practice
Chrysalyne Schmults, MD, of Brigham and Women’s Hospital, discusses treatment strategies in these nonmelanoma skin cancers, including surgery, forthcoming staging systems, an...
Gary H. Lyman, MD, MPH, on Myeloid Growth Factors: New Biosimilar Approvals
Gary H. Lyman, MD, MPH, of the Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, discusses current strategies for the use of biosimilars to treat cancer-in...
Wells A. Messersmith, MD, on Managing Metastatic Colorectal Cancer: NCCN Guidelines Update
Wells A. Messersmith, MD, of the University of Colorado Cancer Center, discusses results of recent clinical trials, emerging treatment options, and approaches that may improv...
Neil P. Shah, MD, PhD, on CML: NCCN Guidelines Updates on Discontinuing Tyrosine Kinase Inhibitor Therapy
Neil P. Shah, MD, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the feasibility of discontinuing tyrosine kinase inhibitor therapy in select pat...
